Data gathered: July 5
AI Stock Analysis - ARS Pharmaceuticals (SPRY)
Analysis generated March 14, 2025. Powered by Chat GPT.
ARS Pharmaceuticals is a biopharmaceutical company focused on developing innovative and life-saving therapies. The company's primary focus lies on targeted treatments designed to significantly improve patient outcomes. The company has recently garnered attention due to its promising pipeline of products and steady growth in the pharmaceutical sector. However, some internal and external factors indicate potential concerns that warrant a thorough analysis.
Stock Alerts - ARS Pharmaceuticals (SPRY)
 |
ARS Pharmaceuticals | July 4 Insider Alert: Karas Eric is continuing selling shares |
|
ARS Pharmaceuticals | July 2 Insider Alert: DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) is selling shares |
|
ARS Pharmaceuticals | July 1 Price is down by -8.2% in the last 24h. |
|
ARS Pharmaceuticals | June 30 Price is down by -10.1% in the last 24h. |
Download our app to get future alerts delivered in real-time.
Alternative Data for ARS Pharmaceuticals
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 3 | Sign up | Sign up | Sign up |
| Sentiment | 92 | Sign up | Sign up | Sign up |
| Webpage traffic | 13,000 | Sign up | Sign up | Sign up |
| Employee Rating | 92 | Sign up | Sign up | Sign up |
| Google Trends | 27 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 13 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 2,112 | Sign up | Sign up | Sign up |
| Twitter Followers | 521 | Sign up | Sign up | Sign up |
| Twitter Mentions | N/A | Sign up | Sign up | Sign up |
| News Mentions | 1 | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 66 | Sign up | Sign up | Sign up |
| Linkedin Employees | 163 | Sign up | Sign up | Sign up |
About ARS Pharmaceuticals
ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for severe allergic reactions.
| Price | $16.52 |
| Target Price | Sign up |
| Volume | 880,530 |
| Market Cap | $1.62B |
| Year Range | $10.18 - $18.2 |
| Dividend Yield | 0% |
| PE Ratio | 152.44 |
| Analyst Rating | 100% buy |
| Industry | Biotechnology |
In the news
 |
Oppenheimer & Co. Inc. Takes Position in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)July 4 - ETF Daily News |
|
Insider Selling: ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Major Shareholder Sells 740,149 Shares of StockJuly 3 - ETF Daily News |
ARS Pharmaceuticals, Inc.(NasdaqGM: SPRY) dropped from Russell Microcap Growth IndexJune 30 - Finnhub |
|
ARS Pharmaceuticals, Inc.(NasdaqGM: SPRY) dropped from Russell 3000E Growth IndexJune 30 - Finnhub |
|
ARS Pharmaceuticals, Inc.(NasdaqGM: SPRY) dropped from Russell 3000E IndexJune 30 - Finnhub |
|
ARS Pharmaceuticals, Inc.(NasdaqGM: SPRY) added to Russell 2000 Growth-Defensive IndexJune 30 - Finnhub |
|
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q1 '25 | 8M | 1.1M | 6.9M | -34M | -37M | -0.350 |
| Q4 '24 | 87M | 870,000 | 86M | 50M | 47M | 0.510 |
| Q3 '24 | 2.1M | 110,000 | 1.9M | -19M | -22M | -0.200 |
| Q2 '24 | 500,000 | 18,000 | 480,000 | -13M | -15M | -0.130 |
| Q1 '24 | 0 | 11,000 | -11,000 | -10M | -13M | -0.110 |
Insider Transactions View All
| Karas Eric filed to sell 10,315 shares at $17. July 3 '25 |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) filed to sell 4,887,254 shares at $18.5. July 1 '25 |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) filed to sell 4,887,254 shares at $18.5. July 1 '25 |
| Karas Eric filed to sell 7,696 shares at $16. June 20 '25 |
| Scott Kathleen D. filed to sell 7,424 shares at $14.1. May 22 '25 |
Similar companies
Read more about ARS Pharmaceuticals (SPRY) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, news mentions, customer reviews, business outlook & linkedin employees.
What is the Market Cap of ARS Pharmaceuticals?
The Market Cap of ARS Pharmaceuticals is $1.62B.
What is ARS Pharmaceuticals' PE Ratio?
As of today, ARS Pharmaceuticals' PE (Price to Earnings) ratio is 152.44.
What is the current stock price of ARS Pharmaceuticals?
Currently, the price of one share of ARS Pharmaceuticals stock is $16.52.
How can I analyze the SPRY stock price chart for investment decisions?
The SPRY stock price chart above provides a comprehensive visual representation of ARS Pharmaceuticals' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling ARS Pharmaceuticals shares. Our platform offers an up-to-date SPRY stock price chart, along with technical data analysis and alternative data insights.
Does SPRY offer dividends to its shareholders?
As of our latest update, ARS Pharmaceuticals (SPRY) does not offer dividends to its shareholders. Investors interested in ARS Pharmaceuticals should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of ARS Pharmaceuticals?
Some of the similar stocks of ARS Pharmaceuticals are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.